Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SSGJ-621
- Development stage
- Unknown
- Lead developer
- 3S Guojian Pharmaceutical
- Modality
- Antibody-Based Therapeutics
01
Overview
SSGJ-621: sourced facts only. name: "Here we describe a novel anti-IL33 humanized monoclonal antibody, SSGJ-621, which bound IL-33 with high affinity and blocked the interaction between IL-33 and ST2." [DOI:10.1158/1538-7445.am2022-6191]; target: "Here we describe a novel anti-IL33 humanized monoclonal antibody, SSGJ-621, which bound IL-33 with high affinity and blocked the interaction between IL-33 and ST2." [DOI:10.1158/1538-7445.am2022-6191]; developer: "1Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Shanghai, China." [DOI:10.1158/1538-7445.am2022-6191]; modality: "Here we describe a novel anti-IL33 humanized monoclonal antibody, SSGJ-621, which bound IL-33 with high affinity and blocked the interaction between IL-33 and ST2." [DOI:10.1158/1538-7445.am2022-6191]
02
Targets
IL33 (IL-33)
Beyond the preview
Go deeper on SSGJ-621.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SSGJ-621.